<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a Phase I/II clinical trial, 13 higher risk red blood cell-dependent <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients unresponsive to hypomethylating therapy were treated with the multikinase inhibitor ON 01910.Na </plain></SENT>
<SENT sid="1" pm="."><plain>Responses occurred in <z:hpo ids='HP_0000001'>all</z:hpo> morphologic, prognostic risk and cytogenetic subgroups, including four patients with marrow complete responses among eight with stable disease, associated with good drug tolerance </plain></SENT>
<SENT sid="2" pm="."><plain>In a subset of patients, a novel nanoscale immunoassay showed substantially decreased AKT2 phosphorylation in CD34+ marrow cells from patients responding to therapy but not those who progressed on therapy </plain></SENT>
<SENT sid="3" pm="."><plain>These data demonstrate encouraging efficacy and drug tolerance with ON 01910.Na treatment of higher risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>